SIMILAR PATTERNS OF AMINO ACIDS FOR 4ANS_A_VGHA9000

List of similar pattern of amino acids derived from ASSAM search

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click link on the last column to view superposed patterns of amino acids in NGL viewer)
(Note that only 3-12 residue patterns can be used for ASSAM searches)

Filter list by:

	Hit	Macromolecule/ Organism	Pfam	Res.	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1k9a	CARBOXYL-TERMINAL SRC KINASE (Rattus norvegicus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	6	VAL A 209 ALA A 220 MET A 269 GLY A 272 LEU A 321 ASP A 332	None	0.71A	4ansA-1k9aA: 32.4	4ansA-1k9aA: 26.86
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1luf	MUSCLE-SPECIFIC TYROSINE KINASE RECEPTOR MUSK (Rattus norvegicus)	PF07714 (Pkinase_Tyr)	6	VAL A 588 ALA A 606 MET A 657 GLY A 660 LEU A 731 ALA A 741	None	0.65A	4ansA-1lufA: 32.6	4ansA-1lufA: 36.01
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1luf	MUSCLE-SPECIFIC TYROSINE KINASE RECEPTOR MUSK (Rattus norvegicus)	PF07714 (Pkinase_Tyr)	6	VAL A 588 ALA A 606 MET A 657 LEU A 731 ALA A 741 ASP A 742	None	0.69A	4ansA-1lufA: 32.6	4ansA-1lufA: 36.01
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1opk	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Mus musculus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	6	LEU A 267 VAL A 275 ALA A 288 MET A 337 GLY A 340 LEU A 389	P16 A 2 ( 4.2A) P16 A 2 (-4.5A) P16 A 2 (-3.4A) None P16 A 2 (-3.4A) P16 A 2 (-4.4A)	0.57A	4ansA-1opkA: 30.5	4ansA-1opkA: 27.54
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1s9i	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 78 VAL A 86 ALA A 99 MET A 147 MET A 150 GLY A 153 LEU A 201	ATP A 535 (-3.9A) ATP A 535 (-4.1A) ATP A 535 (-3.6A) ATP A 535 ( 3.4A) None ATP A 535 ( 4.7A) ATP A 535 (-4.8A)	0.53A	4ansA-1s9iA: 21.8	4ansA-1s9iA: 25.12
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1u59	TYROSINE-PROTEIN KINASE ZAP-70 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 344 VAL A 352 ALA A 367 MET A 414 GLY A 420 LEU A 468	STU A 100 (-3.8A) STU A 100 (-4.8A) STU A 100 (-3.2A) STU A 100 (-3.6A) STU A 100 (-3.5A) STU A 100 (-4.5A)	0.71A	4ansA-1u59A: 31.8	4ansA-1u59A: 32.18
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2dq7	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU X 17 VAL X 25 ALA X 37 MET X 85 GLY X 88 LEU X 137 ALA X 147 ASP X 148	STU X 902 (-3.8A) STU X 902 ( 4.8A) STU X 902 (-3.1A) None STU X 902 (-3.5A) STU X 902 (-4.4A) STU X 902 ( 4.1A) STU X 902 (-3.6A)	0.81A	4ansA-2dq7X: 31.3	4ansA-2dq7X: 37.82
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2f9g	MITOGEN-ACTIVATED PROTEIN KINASE FUS3 (Saccharomyces cerevisiae)	PF00069 (Pkinase)	6	LEU A 19 VAL A 27 ALA A 40 MET A 96 LEU A 144 ASP A 155	ADP A 500 (-4.3A) ADP A 500 (-4.3A) ADP A 500 ( 3.7A) None ADP A 500 (-4.3A) ADP A 500 ( 2.9A)	0.72A	4ansA-2f9gA: 22.2	4ansA-2f9gA: 23.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2h8h	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	8	LEU A 273 VAL A 281 ALA A 293 MET A 341 GLY A 344 LEU A 393 ALA A 403 ASP A 404	H8H A 534 (-3.8A) H8H A 534 (-4.4A) H8H A 534 (-3.2A) None H8H A 534 (-3.3A) H8H A 534 (-4.5A) H8H A 534 ( 4.0A) H8H A 534 (-4.2A)	0.77A	4ansA-2h8hA: 29.9	4ansA-2h8hA: 24.20
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2hck	HEMATOPOETIC CELL KINASE HCK (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	7	LEU A 273 VAL A 281 ALA A 293 MET A 341 GLY A 344 LEU A 393 ALA A 403	QUE A 1 (-3.9A) QUE A 1 ( 4.8A) QUE A 1 (-3.5A) None QUE A 1 (-3.0A) QUE A 1 (-4.4A) QUE A 1 ( 4.5A)	0.79A	4ansA-2hckA: 28.9	4ansA-2hckA: 27.35
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hk5	TYROSINE-PROTEIN KINASE HCK (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 251 VAL A 259 ALA A 271 MET A 319 GLY A 322 LEU A 371 ALA A 381 ASP A 382	1BM A 499 ( 3.7A) 1BM A 499 ( 4.8A) 1BM A 499 (-3.6A) None 1BM A 499 (-3.5A) 1BM A 499 (-4.4A) 1BM A 499 ( 3.7A) 1BM A 499 (-4.4A)	0.56A	4ansA-2hk5A: 24.9	4ansA-2hk5A: 37.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2hz0	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	8	LEU A 248 VAL A 256 ALA A 269 MET A 318 GLY A 321 LEU A 370 ALA A 380 ASP A 381	GIN A 600 ( 4.6A) GIN A 600 ( 4.7A) GIN A 600 (-3.1A) None None GIN A 600 (-4.7A) GIN A 600 (-3.1A) GIN A 600 (-4.9A)	0.96A	4ansA-2hz0A: 30.7	4ansA-2hz0A: 35.96
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2og8	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 251 VAL A 259 ALA A 271 MET A 319 GLY A 322 LEU A 371 ALA A 381	None None 1N8 A 501 ( 3.4A) 1N8 A 501 ( 4.4A) 1N8 A 501 ( 3.5A) 1N8 A 501 ( 4.3A) 1N8 A 501 ( 3.3A)	0.88A	4ansA-2og8A: 30.1	4ansA-2og8A: 40.48
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2ozo	TYROSINE-PROTEIN KINASE ZAP-70 (Homo sapiens)	PF00017 (SH2) PF07714 (Pkinase_Tyr)	6	LEU A 344 VAL A 352 ALA A 367 MET A 414 GLY A 420 LEU A 468	ANP A 615 (-4.4A) ANP A 615 (-4.5A) ANP A 615 (-3.3A) ANP A 615 ( 3.9A) ANP A 615 ( 3.9A) ANP A 615 (-4.7A)	0.63A	4ansA-2ozoA: 24.6	4ansA-2ozoA: 21.94
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2phk	PHOSPHORYLASE KINASE (Oryctolagus cuniculus)	PF00069 (Pkinase)	7	LEU A 25 VAL A 33 ALA A 46 MET A 106 GLY A 109 LEU A 156 ASP A 167	ATP A 381 ( 4.3A) ATP A 381 (-4.1A) ATP A 381 (-3.5A) None None ATP A 381 ( 4.8A) MN A 382 (-2.0A)	0.72A	4ansA-2phkA: 22.6	4ansA-2phkA: 23.40
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2psq	FIBROBLAST GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 487 VAL A 495 ALA A 515 GLY A 570 LEU A 633 ALA A 643	None	0.55A	4ansA-2psqA: 31.6	4ansA-2psqA: 36.15
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2qkw	PROTEIN KINASE (Solanum pimpinellifolium)	PF07714 (Pkinase_Tyr)	6	VAL B 55 ALA B 67 MET B 117 GLY B 120 LEU B 171 ASP B 182	None	0.61A	4ansA-2qkwB: 24.1	4ansA-2qkwB: 27.20
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2qob	EPHRIN RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 635 ALA A 651 MET A 702 GLY A 705 LEU A 753 ASP A 764	BME A 1 (-4.9A) PTR A 701 ( 4.7A) PTR A 701 ( 3.5A) None None None	0.41A	4ansA-2qobA: 34.0	4ansA-2qobA: 32.56
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2r2p	EPHRIN TYPE-A RECEPTOR 5 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14575 (EphA2_TM)	6	VAL A 689 ALA A 705 MET A 756 GLY A 759 LEU A 807 ASP A 818	None	0.32A	4ansA-2r2pA: 34.1	4ansA-2r2pA: 32.86
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2r4b	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 724 VAL A 732 ALA A 749 MET A 799 GLY A 802 LEU A 850	GW7 A 1 ( 4.2A) GW7 A 1 ( 4.8A) GW7 A 1 (-3.3A) None GW7 A 1 (-3.6A) GW7 A 1 (-4.2A)	0.57A	4ansA-2r4bA: 30.0	4ansA-2r4bA: 33.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2v55	RHO-ASSOCIATED PROTEIN KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 90 ALA A 103 MET A 153 MET A 156 GLY A 159 ALA A 215 ASP A 216	None ANP A1480 ( 3.9A) ANP A1480 (-4.1A) None None ANP A1480 ( 4.1A) ANP A1480 (-3.5A)	0.88A	4ansA-2v55A: 19.5	4ansA-2v55A: 23.96
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2v55	RHO-ASSOCIATED PROTEIN KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	7	VAL A 90 ALA A 103 MET A 156 GLY A 159 LEU A 205 ALA A 215 ASP A 216	None ANP A1480 ( 3.9A) None None ANP A1480 ( 4.7A) ANP A1480 ( 4.1A) ANP A1480 (-3.5A)	0.99A	4ansA-2v55A: 19.5	4ansA-2v55A: 23.96
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2xk9	CHECKPOINT KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 226 VAL A 234 ALA A 247 MET A 304 GLY A 307 LEU A 354 ASP A 368	XK9 A1511 (-3.8A) XK9 A1511 (-4.8A) XK9 A1511 ( 4.1A) None XK9 A1511 ( 3.7A) XK9 A1511 (-4.6A) XK9 A1511 (-3.6A)	0.76A	4ansA-2xk9A: 21.3	4ansA-2xk9A: 24.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2xyu	EPHRIN TYPE-A RECEPTOR 4, (Mus musculus)	PF07714 (Pkinase_Tyr)	6	VAL A 635 ALA A 651 MET A 702 GLY A 705 LEU A 753 ASP A 764	Q9G A1898 ( 4.7A) Q9G A1898 (-3.2A) None Q9G A1898 ( 3.8A) Q9G A1898 (-4.3A) None	0.58A	4ansA-2xyuA: 27.2	4ansA-2xyuA: 34.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2z8c	INSULIN RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A1002 VAL A1010 ALA A1028 MET A1076 MET A1079 GLY A1082 ASP A1150	S91 A 1 ( 4.1A) S91 A 1 ( 4.9A) S91 A 1 (-3.2A) S91 A 1 ( 4.9A) None S91 A 1 (-3.3A) None	0.67A	4ansA-2z8cA: 30.1	4ansA-2z8cA: 44.41
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2zv7	TYROSINE-PROTEIN KINASE LYN (Mus musculus)	PF07714 (Pkinase_Tyr)	8	LEU A 253 VAL A 261 ALA A 273 MET A 322 GLY A 325 LEU A 374 ALA A 384 ASP A 385	None	0.47A	4ansA-2zv7A: 32.4	4ansA-2zv7A: 34.49
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3b2t	FIBROBLAST GROWTH FACTOR RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 487 VAL A 495 ALA A 515 GLY A 570 LEU A 633 ALA A 643	M33 A1996 (-4.0A) M33 A1996 ( 4.7A) M33 A1996 (-3.3A) M33 A1996 ( 4.8A) M33 A1996 (-4.5A) None	0.54A	4ansA-3b2tA: 24.5	4ansA-3b2tA: 35.21
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3d7u	TYROSINE-PROTEIN KINASE CSK (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 209 ALA A 220 MET A 269 GLY A 272 LEU A 321 ASP A 332	None	0.71A	4ansA-3d7uA: 27.3	4ansA-3d7uA: 32.94
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3fme	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6 (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 59 VAL A 67 ALA A 80 MET A 129 MET A 132 LEU A 186	STU A 1 (-3.8A) None STU A 1 (-3.4A) STU A 1 ( 3.8A) None STU A 1 (-4.4A)	0.57A	4ansA-3fmeA: 21.1	4ansA-3fmeA: 27.06
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3g2f	BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-2 (Homo sapiens)	PF00069 (Pkinase)	6	VAL A 217 ALA A 228 MET A 279 GLY A 285 LEU A 340 ASP A 351	ADP A 900 (-4.3A) ADP A 900 (-3.4A) ADP A 900 (-3.6A) ADP A 900 ( 4.2A) ADP A 900 (-4.6A) ADP A 900 ( 2.7A)	0.64A	4ansA-3g2fA: 18.4	4ansA-3g2fA: 26.86
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3lw0	INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A1005 VAL A1013 ALA A1031 MET A1079 MET A1082 GLY A1085	None None None CCX A 1 ( 3.9A) None None	0.45A	4ansA-3lw0A: 29.9	4ansA-3lw0A: 39.89
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3niz	RHODANESE FAMILY PROTEIN (Cryptosporidium parvum)	PF00069 (Pkinase)	6	VAL A 37 ALA A 49 MET A 101 LEU A 151 ALA A 161 ASP A 162	ADP A 314 (-4.0A) ADP A 314 (-3.5A) None ADP A 314 (-4.6A) None MG A 312 ( 3.3A)	0.52A	4ansA-3nizA: 24.3	4ansA-3nizA: 29.30
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3nyo	G PROTEIN-COUPLED RECEPTOR KINASE 6 (Homo sapiens)	PF00069 (Pkinase) PF00615 (RGS)	7	LEU A 192 VAL A 200 ALA A 213 MET A 266 GLY A 269 LEU A 318 ASP A 329	AMP A 577 ( 4.3A) AMP A 577 (-4.3A) AMP A 577 (-3.4A) None None AMP A 577 (-4.8A) AMP A 577 (-4.0A)	0.75A	4ansA-3nyoA: 22.6	4ansA-3nyoA: 21.18
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3pp0	RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 726 VAL A 734 ALA A 751 MET A 801 GLY A 804 LEU A 852	03Q A 1 (-3.8A) 03Q A 1 (-4.5A) 03Q A 1 (-3.1A) None 03Q A 1 ( 3.9A) 03Q A 1 (-4.4A)	0.52A	4ansA-3pp0A: 31.1	4ansA-3pp0A: 33.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3she	MAP KINASE-ACTIVATED PROTEIN KINASE 3 (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 50 VAL A 58 ALA A 71 MET A 118 MET A 121 GLY A 124 LEU A 173	I85 A 350 (-3.7A) I85 A 350 (-4.9A) I85 A 350 (-3.3A) I85 A 350 ( 3.9A) None I85 A 350 (-3.0A) None	1.01A	4ansA-3sheA: 19.6	4ansA-3sheA: 23.77
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3ulz	BRASSINOSTEROID INSENSITIVE 1-ASSOCIATED RECEPTOR KINASE 1 (Arabidopsis thaliana)	PF00069 (Pkinase)	6	LEU A 295 VAL A 303 ALA A 315 MET A 366 GLY A 369 LEU A 423	None	0.53A	4ansA-3ulzA: 22.1	4ansA-3ulzA: 27.69
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3v5q	NT-3 GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 544 VAL A 552 ALA A 570 MET A 620 GLY A 623 LEU A 686	0F4 A 902 ( 4.2A) None 0F4 A 902 (-3.2A) None 0F4 A 902 (-3.4A) 0F4 A 902 (-4.5A)	0.31A	4ansA-3v5qA: 14.8	4ansA-3v5qA: 37.32
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3vn9	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6 (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 59 VAL A 67 ALA A 80 MET A 129 MET A 132 LEU A 186	None ANK A 401 (-4.3A) ANK A 401 (-3.0A) ANK A 401 (-3.7A) None ANK A 401 ( 4.9A)	0.69A	4ansA-3vn9A: 21.6	4ansA-3vn9A: 26.80
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3wig	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 75 VAL A 83 ALA A 96 MET A 144 MET A 147 GLY A 150 LEU A 198	ANP A 401 (-3.8A) ANP A 401 ( 4.3A) ANP A 401 (-3.2A) CHU A 403 (-3.8A) None ANP A 401 ( 4.3A) ANP A 401 (-4.8A)	0.44A	4ansA-3wigA: 22.9	4ansA-3wigA: 24.27
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3zbf	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A1951 VAL A1959 ALA A1978 MET A2029 GLY A2032 LEU A2086 ASP A2102	VGH A3000 ( 4.4A) None VGH A3000 (-3.4A) None VGH A3000 (-3.5A) VGH A3000 (-4.3A) None	0.33A	4ansA-3zbfA: 34.4	4ansA-3zbfA: 49.27
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3zfx	EPHRIN TYPE-B RECEPTOR 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 633 ALA A 649 MET A 700 GLY A 703 LEU A 751 ASP A 762	None	0.44A	4ansA-3zfxA: 34.3	4ansA-3zfxA: 35.10
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4af3	AURORA KINASE B (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 83 VAL A 91 ALA A 104 GLY A 160 LEU A 207 ALA A 217	VX6 A 500 (-3.8A) VX6 A 500 ( 4.8A) VX6 A 500 (-3.4A) VX6 A 500 (-3.3A) VX6 A 500 (-4.6A) VX6 A 500 ( 4.2A)	0.60A	4ansA-4af3A: 19.7	4ansA-4af3A: 24.42
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4at3	BDNF/NT-3 GROWTH FACTORS RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 560 VAL A 568 ALA A 586 MET A 636 GLY A 639 LEU A 699 ASP A 710	LTI A1839 ( 4.2A) None LTI A1839 (-3.3A) None LTI A1839 (-3.4A) LTI A1839 (-4.2A) None	0.47A	4ansA-4at3A: 31.0	4ansA-4at3A: 36.78
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4aw5	EPHRIN TYPE-B RECEPTOR 4 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 105 ALA A 121 MET A 172 GLY A 175 LEU A 223 ASP A 234	30K A1365 ( 4.6A) 30K A1365 (-3.2A) None 30K A1365 (-3.5A) 30K A1365 (-4.5A) 30K A1365 (-3.3A)	0.35A	4ansA-4aw5A: 33.8	4ansA-4aw5A: 34.53
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4bc6	SERINE/THREONINE-PRO TEIN KINASE 10 (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 42 VAL A 50 ALA A 63 GLY A 116 LEU A 164 ALA A 174	XZN A1317 (-3.6A) XZN A1317 ( 4.7A) XZN A1317 (-3.5A) XZN A1317 ( 3.7A) XZN A1317 (-4.7A) XZN A1317 ( 4.3A)	0.53A	4ansA-4bc6A: 23.5	4ansA-4bc6A: 27.52
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4crs	SERINE/THREONINE-PRO TEIN KINASE N2 (Homo sapiens)	PF00069 (Pkinase) PF00433 (Pkinase_C)	8	LEU A 663 VAL A 671 ALA A 684 MET A 737 GLY A 743 LEU A 789 ALA A 799 ASP A 800	AGS A1985 (-4.2A) AGS A1985 (-4.6A) AGS A1985 (-3.5A) AGS A1985 (-4.2A) None AGS A1985 (-4.8A) AGS A1985 ( 4.5A) AGS A1985 ( 3.3A)	0.78A	4ansA-4crsA: 21.6	4ansA-4crsA: 27.18
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4f0i	HIGH AFFINITY NERVE GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 515 VAL A 523 ALA A 541 MET A 591 GLY A 594 LEU A 656 ASP A 667	None	0.59A	4ansA-4f0iA: 30.8	4ansA-4f0iA: 37.24
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4f4p	TYROSINE-PROTEIN KINASE SYK (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 377 VAL A 385 ALA A 400 MET A 448 GLY A 454 LEU A 501 ASP A 512	0SB A 701 ( 3.9A) 0SB A 701 (-4.0A) 0SB A 701 (-3.3A) 0SB A 701 (-3.6A) 0SB A 701 (-3.5A) 0SB A 701 (-4.4A) 0SB A 701 (-3.9A)	0.65A	4ansA-4f4pA: 31.4	4ansA-4f4pA: 31.69
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4feq	TYROSINE-PROTEIN KINASE RECEPTOR TYRO3 (Mus musculus)	PF07714 (Pkinase_Tyr)	7	LEU A 514 VAL A 522 ALA A 538 MET A 596 GLY A 599 ALA A 662 ASP A 663	0T8 A 901 (-3.6A) 0T8 A 901 ( 4.4A) 0T8 A 901 (-3.2A) None 0T8 A 901 ( 3.8A) 0T8 A 901 ( 4.5A) 0T8 A 901 (-4.5A)	0.86A	4ansA-4feqA: 22.2	4ansA-4feqA: 35.81
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4fl3	TYROSINE-PROTEIN KINASE SYK (Homo sapiens)	PF00017 (SH2) PF07714 (Pkinase_Tyr)	6	LEU A 377 VAL A 385 ALA A 400 MET A 448 GLY A 454 LEU A 501	ANP A 701 ( 4.6A) ANP A 701 (-4.1A) ANP A 701 (-3.3A) ANP A 701 ( 3.7A) ANP A 701 ( 4.2A) ANP A 701 (-4.5A)	0.42A	4ansA-4fl3A: 29.4	4ansA-4fl3A: 20.66
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4fod	ALK TYROSINE KINASE RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A1122 VAL A1130 ALA A1148 MET A1199 GLY A1202 LEU A1256 ASP A1270	0UV A1501 (-3.8A) 0UV A1501 (-4.5A) 0UV A1501 (-3.4A) None 0UV A1501 (-3.6A) 0UV A1501 (-4.6A) 0UV A1501 ( 4.2A)	0.34A	4ansA-4fodA: 46.3	4ansA-4fodA: 93.26
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4gl9	TYROSINE-PROTEIN KINASE (Mus musculus)	PF07714 (Pkinase_Tyr)	6	LEU A 855 VAL A 863 ALA A 880 MET A 929 GLY A 935 LEU A 983	IZA A2001 (-3.7A) None IZA A2001 (-3.4A) IZA A2001 (-4.4A) IZA A2001 (-3.3A) IZA A2001 ( 4.7A)	0.61A	4ansA-4gl9A: 28.8	4ansA-4gl9A: 29.91
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4hvi	TYROSINE-PROTEIN KINASE JAK3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	ALA A 853 MET A 902 GLY A 908 LEU A 956 ALA A 966 ASP A 967	19S A1201 (-3.3A) 19S A1201 (-3.6A) 19S A1201 ( 3.8A) 19S A1201 (-4.5A) 19S A1201 ( 4.1A) 19S A1201 ( 4.1A)	0.54A	4ansA-4hviA: 29.7	4ansA-4hviA: 28.73
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4hvi	TYROSINE-PROTEIN KINASE JAK3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 828 VAL A 836 ALA A 853 MET A 902 GLY A 908 LEU A 956 ALA A 966	19S A1201 (-3.9A) 19S A1201 (-4.4A) 19S A1201 (-3.3A) 19S A1201 (-3.6A) 19S A1201 ( 3.8A) 19S A1201 (-4.5A) 19S A1201 ( 4.1A)	0.80A	4ansA-4hviA: 29.7	4ansA-4hviA: 28.73
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4id7	ACTIVATED CDC42 KINASE 1 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 132 VAL A 140 ALA A 156 GLY A 211 LEU A 259 ASP A 270	1G0 A 401 ( 4.5A) 1G0 A 401 (-4.4A) 1G0 A 401 (-3.6A) 1G0 A 401 ( 4.5A) 1G0 A 401 (-4.6A) None	0.64A	4ansA-4id7A: 30.9	4ansA-4id7A: 33.63
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4jrn	RHOPTRY KINASE FAMILY PROTEIN (Toxoplasma gondii)	PF14531 (Kinase-like)	6	LEU A 258 VAL A 266 ALA A 279 MET A 356 LEU A 416 ASP A 427	ANP A 601 ( 4.6A) ANP A 601 (-4.1A) ANP A 601 ( 3.9A) ANP A 601 (-3.3A) ANP A 601 ( 4.9A) MG A 603 ( 2.0A)	0.53A	4ansA-4jrnA: 19.8	4ansA-4jrnA: 24.23
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4jxf	SERINE/THREONINE-PRO TEIN KINASE PLK4 (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 18 VAL A 26 ALA A 39 GLY A 95 LEU A 143 ALA A 153 ASP A 154	631 A 301 (-3.4A) 631 A 301 (-4.6A) 631 A 301 (-3.3A) 631 A 301 ( 3.7A) 631 A 301 (-4.0A) 631 A 301 (-3.4A) EDO A 302 (-3.7A)	0.67A	4ansA-4jxfA: 18.8	4ansA-4jxfA: 23.89
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4k11	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Homo sapiens)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	7	LEU A 273 VAL A 281 ALA A 293 MET A 341 GLY A 344 LEU A 393 ALA A 403	0J9 A 601 (-4.0A) 0J9 A 601 (-4.4A) 0J9 A 601 (-3.3A) None 0J9 A 601 ( 4.1A) 0J9 A 601 (-4.5A) 0J9 A 601 (-3.5A)	0.56A	4ansA-4k11A: 29.8	4ansA-4k11A: 27.73
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4k33	FIBROBLAST GROWTH FACTOR RECEPTOR 3 (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 478 VAL A 486 ALA A 506 GLY A 561 LEU A 624 ALA A 634 ASP A 635	ACP A 801 (-3.8A) ACP A 801 (-4.2A) ACP A 801 (-3.3A) ACP A 801 ( 4.6A) ACP A 801 (-4.4A) None MG A 802 ( 3.0A)	0.66A	4ansA-4k33A: 32.2	4ansA-4k33A: 37.96
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4lg4	SERINE/THREONINE-PRO TEIN KINASE 3 (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 33 VAL A 41 ALA A 54 MET A 99 GLY A 105 LEU A 153 ALA A 163	GOL A 404 ( 3.6A) GOL A 404 (-4.5A) GOL A 404 ( 3.1A) GOL A 403 (-2.7A) GOL A 404 (-3.6A) GOL A 403 ( 4.4A) GOL A 403 ( 3.0A)	0.63A	4ansA-4lg4A: 18.2	4ansA-4lg4A: 26.63
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4lgg	PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC (Gallus gallus)	PF07714 (Pkinase_Tyr)	7	LEU A 273 VAL A 281 ALA A 293 MET A 341 GLY A 344 LEU A 393 ALA A 403	VGG A 601 (-3.2A) VGG A 601 ( 3.5A) VGG A 601 (-3.5A) None VGG A 601 ( 3.2A) VGG A 601 (-4.5A) VGG A 601 ( 4.2A)	0.44A	4ansA-4lggA: 29.8	4ansA-4lggA: 33.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4o27	SERINE/THREONINE-PRO TEIN KINASE 24 (Homo sapiens)	PF00069 (Pkinase)	6	VAL B 38 ALA B 51 MET B 99 LEU B 151 ALA B 161 ASP B 162	ADP B 500 (-4.5A) ADP B 500 (-3.3A) ADP B 500 ( 4.1A) ADP B 500 (-4.7A) None ADP B 500 ( 3.4A)	0.59A	4ansA-4o27B: 18.2	4ansA-4o27B: 26.01
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4oli	NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 903 VAL A 911 ALA A 928 MET A 978 GLY A 984 LEU A1030	2TT A1202 (-3.5A) 2TT A1202 (-4.5A) 2TT A1202 ( 3.9A) 2TT A1202 ( 4.4A) 2TT A1202 (-3.4A) 2TT A1202 (-4.4A)	0.71A	4ansA-4oliA: 27.1	4ansA-4oliA: 23.40
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4otd	SERINE/THREONINE-PRO TEIN KINASE N1 (Homo sapiens)	PF00069 (Pkinase) PF00433 (Pkinase_C)	7	LEU A 627 VAL A 635 ALA A 648 GLY A 707 LEU A 753 ALA A 763 ASP A 764	None	1.13A	4ansA-4otdA: 21.9	4ansA-4otdA: 27.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4p2k	EPHRIN TYPE-A RECEPTOR 2 (Homo sapiens)	PF07714 (Pkinase_Tyr) PF14575 (EphA2_TM)	6	VAL A 627 ALA A 644 MET A 695 GLY A 698 LEU A 746 ASP A 757	None	0.50A	4ansA-4p2kA: 34.5	4ansA-4p2kA: 36.58
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4qny	MITOGEN ACTIVATED PROTEIN KINASE, PUTATIVE (Leishmania donovani)	PF00069 (Pkinase)	6	VAL A 35 ALA A 49 MET A 104 MET A 107 LEU A 156 ASP A 167	ANP A 402 (-4.3A) ANP A 402 (-3.3A) ANP A 402 (-4.4A) None ANP A 402 (-4.6A) ANP A 402 ( 2.6A)	0.60A	4ansA-4qnyA: 22.4	4ansA-4qnyA: 25.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ueu	TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL (synthetic construct)	PF07714 (Pkinase_Tyr)	8	LEU A 14 VAL A 22 ALA A 35 MET A 84 GLY A 87 LEU A 136 ALA A 146 ASP A 147	ACP A1264 ( 4.5A) ACP A1264 (-4.7A) ACP A1264 (-2.9A) None ACP A1264 (-3.5A) ACP A1264 ( 4.8A) None None	0.48A	4ansA-4ueuA: 32.2	4ansA-4ueuA: 39.47
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4usf	STE20-LIKE SERINE/THREONINE-PRO TEIN KINASE (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 40 VAL A 48 ALA A 61 GLY A 114 LEU A 162 ALA A 172	6UI A 700 ( 4.9A) None 6UI A 700 (-3.3A) 6UI A 700 ( 4.2A) 6UI A 700 (-4.2A) 6UI A 700 ( 4.1A)	0.56A	4ansA-4usfA: 23.5	4ansA-4usfA: 28.57
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4wbo	RHODOPSIN KINASE (Bos taurus)	PF00069 (Pkinase) PF00615 (RGS)	8	LEU A 193 VAL A 201 ALA A 214 MET A 264 MET A 267 GLY A 270 LEU A 321 ASP A 332	ANW A 601 ( 4.0A) None ANW A 601 (-3.4A) ANW A 601 (-3.2A) None ANW A 601 ( 4.5A) ANW A 601 (-4.9A) None	0.65A	4ansA-4wboA: 23.3	4ansA-4wboA: 22.39
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4wsq	AP2-ASSOCIATED PROTEIN KINASE 1 (Homo sapiens)	PF00069 (Pkinase)	7	LEU A 52 VAL A 60 ALA A 72 MET A 126 GLY A 132 LEU A 183 ASP A 194	KSA A 405 ( 4.0A) KSA A 405 ( 4.9A) KSA A 405 (-3.2A) KSA A 405 ( 3.7A) KSA A 405 (-3.5A) KSA A 405 (-4.6A) ZN A 403 ( 2.6A)	0.87A	4ansA-4wsqA: 23.4	4ansA-4wsqA: 24.52
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	no annotation	6	LEU B 267 VAL B 275 ALA B 288 GLY B 340 LEU B 389 ALA B 399	1N1 B 601 (-3.7A) 1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A) 1N1 B 601 (-3.5A)	0.65A	4ansA-4xeyB: 25.5	4ansA-4xeyB: 32.86
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4xey	TYROSINE-PROTEIN KINASE ABL1 (Homo sapiens)	no annotation	6	LEU B 267 VAL B 275 ALA B 288 MET B 337 GLY B 340 LEU B 389	1N1 B 601 (-3.7A) 1N1 B 601 ( 4.9A) 1N1 B 601 (-3.5A) None 1N1 B 601 (-3.5A) 1N1 B 601 (-4.3A)	0.34A	4ansA-4xeyB: 25.5	4ansA-4xeyB: 32.86
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4xi2	TYROSINE-PROTEIN KINASE BTK (Mus musculus)	PF00017 (SH2) PF00018 (SH3_1) PF07714 (Pkinase_Tyr)	6	LEU A 408 VAL A 416 ALA A 428 MET A 477 GLY A 480 LEU A 528	None	0.66A	4ansA-4xi2A: 31.2	4ansA-4xi2A: 27.52
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4y93	NON-SPECIFIC PROTEIN-TYROSINE KINASE,NON-SPECIFIC PROTEIN-TYROSINE KINASE (Bos taurus)	PF00169 (PH) PF00779 (BTK) PF07714 (Pkinase_Tyr)	6	LEU A 408 VAL A 416 ALA A 428 MET A 477 GLY A 480 LEU A 528	746 A 702 (-3.8A) 746 A 702 ( 4.3A) 746 A 702 (-2.4A) None 746 A 702 (-3.6A) 746 A 702 (-4.4A)	0.31A	4ansA-4y93A: 31.4	4ansA-4y93A: 27.78
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4yhj	G PROTEIN-COUPLED RECEPTOR KINASE 4 (Homo sapiens)	PF00069 (Pkinase) PF00615 (RGS)	6	LEU A 193 VAL A 201 ALA A 214 MET A 267 LEU A 319 ASP A 330	AN2 A 601 ( 4.2A) AN2 A 601 (-4.0A) AN2 A 601 (-3.6A) None None AN2 A 601 (-3.0A)	0.52A	4ansA-4yhjA: 21.3	4ansA-4yhjA: 21.36
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5a46	FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 484 VAL A 492 ALA A 512 GLY A 567 LEU A 630 ALA A 640	38O A1769 (-3.2A) 38O A1769 (-4.5A) 38O A1769 (-3.6A) 38O A1769 (-3.4A) 38O A1769 (-4.6A) EDO A1766 ( 4.4A)	0.63A	4ansA-5a46A: 31.3	4ansA-5a46A: 35.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5eyk	AURORA KINASE B-A (Xenopus laevis)	PF00069 (Pkinase)	7	LEU A 99 VAL A 107 ALA A 120 GLY A 176 LEU A 223 ALA A 233 ASP A 234	5U5 A 401 (-3.8A) 5U5 A 401 ( 4.3A) 5U5 A 401 (-3.5A) 5U5 A 401 (-3.4A) 5U5 A 401 (-4.7A) None None	0.70A	4ansA-5eykA: 24.5	4ansA-5eykA: 27.27
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5f1z	NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 903 VAL A 911 ALA A 928 MET A 978 GLY A 984 LEU A1030	5U3 A1200 (-3.8A) 5U3 A1200 ( 4.4A) 5U3 A1200 (-3.5A) 5U3 A1200 ( 4.0A) 5U3 A1200 (-3.2A) 5U3 A1200 (-4.4A)	0.60A	4ansA-5f1zA: 27.7	4ansA-5f1zA: 31.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5hor	HEPATOCYTE GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A1092 ALA A1108 MET A1160 GLY A1163 ALA A1221 ASP A1222	63K A1401 (-4.9A) 63K A1401 (-3.5A) None 63K A1401 (-3.6A) 63K A1401 (-3.3A) None	0.59A	4ansA-5horA: 25.7	4ansA-5horA: 33.14
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5hu3	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE TYPE II ALPHA CHAIN (Drosophila melanogaster)	PF00069 (Pkinase)	7	LEU A 20 VAL A 28 ALA A 41 GLY A 96 LEU A 143 ALA A 156 ASP A 157	ADP A 301 ( 4.0A) ADP A 301 (-3.7A) ADP A 301 (-3.5A) None ADP A 301 (-4.7A) ADP A 301 ( 4.8A) MG A 302 ( 3.3A)	0.86A	4ansA-5hu3A: 24.7	4ansA-5hu3A: 25.36
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5i3o	BMP-2-INDUCIBLE PROTEIN KINASE (Homo sapiens)	PF00069 (Pkinase)	6	LEU A 57 VAL A 65 ALA A 77 MET A 130 GLY A 136 LEU A 187	IDV A 401 (-3.8A) IDV A 401 (-4.6A) IDV A 401 (-3.6A) IDV A 401 (-3.4A) IDV A 401 (-3.4A) IDV A 401 (-4.4A)	0.45A	4ansA-5i3oA: 23.6	4ansA-5i3oA: 21.72
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5j5t	MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 3 (Homo sapiens)	PF00069 (Pkinase)	6	ALA A 43 MET A 90 GLY A 96 LEU A 143 ALA A 153 ASP A 154	6G2 A 901 (-3.2A) 6G2 A 901 (-3.5A) 6G2 A 901 (-3.6A) 6G2 A 901 (-4.7A) 6G2 A 901 ( 4.2A) 6G2 A 901 (-3.4A)	0.69A	4ansA-5j5tA: 23.2	4ansA-5j5tA: 25.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5j9z	EPIDERMAL GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 718 VAL A 726 ALA A 743 MET A 790 GLY A 796 LEU A 844	6HJ A1101 ( 4.6A) 6HJ A1101 ( 4.7A) 6HJ A1101 (-3.1A) 6HJ A1101 (-3.4A) 6HJ A1101 ( 4.5A) 6HJ A1101 ( 4.8A)	0.71A	4ansA-5j9zA: 32.4	4ansA-5j9zA: 33.14
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5j9z	EPIDERMAL GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 718 VAL A 726 ALA A 743 MET A 793 GLY A 796 ASP A 855	6HJ A1101 ( 4.6A) 6HJ A1101 ( 4.7A) 6HJ A1101 (-3.1A) None 6HJ A1101 ( 4.5A) 6HJ A1101 (-4.3A)	0.62A	4ansA-5j9zA: 32.4	4ansA-5j9zA: 33.14
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5j9z	EPIDERMAL GROWTH FACTOR RECEPTOR (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	LEU A 718 VAL A 726 ALA A 743 MET A 793 GLY A 796 LEU A 844	6HJ A1101 ( 4.6A) 6HJ A1101 ( 4.7A) 6HJ A1101 (-3.1A) None 6HJ A1101 ( 4.5A) 6HJ A1101 ( 4.8A)	0.29A	4ansA-5j9zA: 32.4	4ansA-5j9zA: 33.14
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5lpy	PROTEIN BRASSINOSTEROID INSENSITIVE 1 (Arabidopsis thaliana)	PF00069 (Pkinase)	6	VAL A 897 ALA A 909 MET A 959 GLY A 962 LEU A1016 ASP A1027	ATP A1200 ( 4.5A) ATP A1200 (-3.5A) None ATP A1200 ( 4.0A) ATP A1200 (-4.6A) ATP A1200 (-4.1A)	0.65A	4ansA-5lpyA: 23.1	4ansA-5lpyA: 25.98
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5lpz	PROTEIN BRASSINOSTEROID INSENSITIVE 1 (Arabidopsis thaliana)	PF00069 (Pkinase)	6	VAL A 897 ALA A 909 MET A 959 GLY A 962 LEU A1016 ASP A1027	ADP A1200 (-4.4A) ADP A1200 (-3.5A) None ADP A1200 ( 4.0A) ADP A1200 (-4.7A) ADP A1200 (-3.4A)	0.53A	4ansA-5lpzA: 23.1	4ansA-5lpzA: 25.66
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5td2	TYROSINE-PROTEIN KINASE MER (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 593 VAL A 601 ALA A 617 MET A 674 GLY A 677 ALA A 740 ASP A 741	7AE A1000 ( 3.9A) 7AE A1000 ( 4.9A) 7AE A1000 (-3.3A) None 7AE A1000 ( 3.7A) 7AE A1000 ( 3.7A) 7AE A1000 (-4.4A)	0.57A	4ansA-5td2A: 28.9	4ansA-5td2A: 34.45
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5u6b	TYROSINE-PROTEIN KINASE RECEPTOR UFO (Homo sapiens)	PF07714 (Pkinase_Tyr)	7	LEU A 542 VAL A 550 ALA A 565 MET A 623 GLY A 626 ALA A 689 ASP A 690	7YS A9001 (-4.1A) 7YS A9001 (-4.2A) 7YS A9001 (-3.3A) 7YS A9001 (-4.7A) 7YS A9001 (-3.4A) 7YS A9001 (-3.4A) None	0.61A	4ansA-5u6bA: 30.2	4ansA-5u6bA: 40.48
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5u7q	RHO-ASSOCIATED PROTEIN KINASE 2 (Homo sapiens)	PF00069 (Pkinase)	8	VAL A 106 ALA A 119 MET A 169 MET A 172 GLY A 175 LEU A 221 ALA A 231 ASP A 232	None	0.69A	4ansA-5u7qA: 20.5	4ansA-5u7qA: 24.47
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5vo1	MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 12 (Homo sapiens)	PF07714 (Pkinase_Tyr)	6	VAL A 139 ALA A 150 MET A 190 GLY A 196 LEU A 243 ASP A 254	9FS A 501 (-4.5A) 9FS A 501 (-3.4A) 9FS A 501 (-3.6A) 9FS A 501 (-3.6A) 9FS A 501 (-4.7A) None	0.66A	4ansA-5vo1A: 26.1	4ansA-5vo1A: 30.79
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5w5j	RECEPTOR-INTERACTING SERINE/THREONINE-PRO TEIN KINASE 2 (Homo sapiens)	no annotation	6	LEU A 24 VAL A 32 ALA A 45 MET A 98 GLY A 101 LEU A 153	9WS A 401 ( 4.2A) 9WS A 401 ( 4.6A) 9WS A 401 (-3.3A) None 9WS A 401 ( 4.3A) 9WS A 401 (-4.6A)	0.54A	4ansA-5w5jA: 22.7	4ansA-5w5jA: 27.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5wnm	RECEPTOR-INTERACTING SERINE/THREONINE-PRO TEIN KINASE 4 (Mus musculus)	no annotation	7	VAL A 36 ALA A 49 MET A 96 MET A 99 GLY A 102 LEU A 150 ASP A 161	VX6 A 402 (-4.6A) VX6 A 402 (-3.2A) VX6 A 402 (-3.7A) None VX6 A 402 (-3.5A) VX6 A 402 (-4.4A) VX6 A 402 (-4.3A)	0.58A	4ansA-5wnmA: 28.1	4ansA-5wnmA: 16.67
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6ao5	SERINE/THREONINE-PRO TEIN KINASE 3 (Homo sapiens)	no annotation	7	LEU A 33 VAL A 41 ALA A 54 MET A 99 GLY A 105 LEU A 153 ALA A 163	ANP A 501 ( 3.8A) ANP A 501 (-4.4A) ANP A 501 ( 3.7A) ANP A 501 (-2.5A) ANP A 501 ( 4.0A) ANP A 501 (-4.6A) None	0.62A	4ansA-6ao5A: 22.4	4ansA-6ao5A: 24.11
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6bql	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE KINASE 2 (Homo sapiens)	no annotation	6	VAL A 179 ALA A 192 GLY A 273 LEU A 319 ALA A 329 ASP A 330	BI9 A 501 ( 4.8A) BI9 A 501 (-3.3A) BI9 A 501 (-3.3A) BI9 A 501 (-4.7A) NH4 A 506 ( 3.7A) None	0.68A	4ansA-6bqlA: 22.7	4ansA-6bqlA: 12.61
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6c7y	TYROSINE-PROTEIN KINASE JAK1 (Homo sapiens)	no annotation	7	LEU A 881 VAL A 889 ALA A 906 MET A 956 GLY A 962 LEU A1010 ASP A1021	ADP A1201 ( 4.5A) ADP A1201 (-4.3A) ADP A1201 (-3.4A) ADP A1201 (-4.2A) ADP A1201 ( 4.1A) ADP A1201 (-4.5A) MG A1203 (-1.8A)	0.69A	4ansA-6c7yA: 28.7	4ansA-6c7yA: 15.18
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6ccf	CALCIUM/CALMODULIN-D EPENDENT PROTEIN KINASE KINASE 1 (Homo sapiens)	no annotation	6	VAL A 142 ALA A 155 GLY A 236 LEU A 282 ALA A 292 ASP A 293	H1N A 501 (-4.4A) H1N A 501 (-3.4A) H1N A 501 (-3.6A) H1N A 501 (-4.8A) H1N A 501 ( 3.9A) H1N A 501 (-3.5A)	0.56A	4ansA-6ccfA: 22.3	4ansA-6ccfA: 13.16
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6cz4	PROTEIN-TYROSINE KINASE 6 (Homo sapiens)	no annotation	6	LEU A 197 VAL A 205 ALA A 217 MET A 267 GLY A 270 LEU A 319	FKY A9001 (-4.1A) FKY A9001 ( 4.6A) FKY A9001 (-3.3A) None FKY A9001 (-3.3A) FKY A9001 ( 4.9A)	0.67A	4ansA-6cz4A: 29.6	4ansA-6cz4A: 17.71
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6f3d	INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 (Homo sapiens)	no annotation	6	VAL A 200 ALA A 211 MET A 265 GLY A 268 LEU A 318 ASP A 329	CJT A 502 ( 4.8A) CJT A 502 (-3.4A) CJT A 502 (-4.9A) CJT A 502 ( 4.3A) CJT A 502 (-4.7A) CJT A 502 ( 4.0A)	0.63A	4ansA-6f3dA: 24.0	4ansA-6f3dA: 13.36
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6fdy	- (-)	no annotation	7	LEU U 20 VAL U 28 ALA U 42 GLY U 97 LEU U 144 ALA U 156 ASP U 157	DB8 U 301 (-3.7A) DB8 U 301 ( 4.8A) DB8 U 301 (-3.6A) DB8 U 301 ( 4.1A) DB8 U 301 (-4.8A) DB8 U 301 ( 4.2A) DB8 U 301 (-3.6A)	0.72A	4ansA-6fdyU: 22.3	4ansA-6fdyU: undetectable

[["4ANS_A_VGHA9000_1","1k9a","Rattus norvegicus","CARBOXYL-TERMINAL SRC KINASE","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",6,"VAL A 209;ALA A 220;MET A 269;GLY A 272;LEU A 321;ASP A 332","None","0.71A","4ansA-1k9aA:32.4","4ansA-1k9aA:26.86"],["4ANS_A_VGHA9000_1","1luf","Rattus norvegicus","MUSCLE-SPECIFIC TYROSINE KINASE RECEPTOR MUSK","PF07714(Pkinase_Tyr)",6,"VAL A 588;ALA A 606;MET A 657;GLY A 660;LEU A 731;ALA A 741","None","0.65A","4ansA-1lufA:32.6","4ansA-1lufA:36.01"],["4ANS_A_VGHA9000_1","1luf","Rattus norvegicus","MUSCLE-SPECIFIC TYROSINE KINASE RECEPTOR MUSK","PF07714(Pkinase_Tyr)",6,"VAL A 588;ALA A 606;MET A 657;LEU A 731;ALA A 741;ASP A 742","None","0.69A","4ansA-1lufA:32.6","4ansA-1lufA:36.01"],["4ANS_A_VGHA9000_1","1opk","Mus musculus","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",6,"LEU A 267;VAL A 275;ALA A 288;MET A 337;GLY A 340;LEU A 389","P16 A   2 ( 4.2A);P16 A   2 (-4.5A);P16 A   2 (-3.4A);None;P16 A   2 (-3.4A);P16 A   2 (-4.4A)","0.57A","4ansA-1opkA:30.5","4ansA-1opkA:27.54"],["4ANS_A_VGHA9000_1","1s9i","Homo sapiens","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 2","PF00069(Pkinase)",7,"LEU A  78;VAL A  86;ALA A  99;MET A 147;MET A 150;GLY A 153;LEU A 201","ATP A 535 (-3.9A);ATP A 535 (-4.1A);ATP A 535 (-3.6A);ATP A 535 ( 3.4A);None;ATP A 535 ( 4.7A);ATP A 535 (-4.8A)","0.53A","4ansA-1s9iA:21.8","4ansA-1s9iA:25.12"],["4ANS_A_VGHA9000_1","1u59","Homo sapiens","TYROSINE-PROTEIN KINASE ZAP-70","PF07714(Pkinase_Tyr)",6,"LEU A 344;VAL A 352;ALA A 367;MET A 414;GLY A 420;LEU A 468","STU A 100 (-3.8A);STU A 100 (-4.8A);STU A 100 (-3.2A);STU A 100 (-3.6A);STU A 100 (-3.5A);STU A 100 (-4.5A)","0.71A","4ansA-1u59A:31.8","4ansA-1u59A:32.18"],["4ANS_A_VGHA9000_1","2dq7","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE FYN","PF07714(Pkinase_Tyr)",8,"LEU X  17;VAL X  25;ALA X  37;MET X  85;GLY X  88;LEU X 137;ALA X 147;ASP X 148","STU X 902 (-3.8A);STU X 902 ( 4.8A);STU X 902 (-3.1A);None;STU X 902 (-3.5A);STU X 902 (-4.4A);STU X 902 ( 4.1A);STU X 902 (-3.6A)","0.81A","4ansA-2dq7X:31.3","4ansA-2dq7X:37.82"],["4ANS_A_VGHA9000_1","2f9g","Saccharomyces cerevisiae","MITOGEN-ACTIVATED PROTEIN KINASE FUS3","PF00069(Pkinase)",6,"LEU A  19;VAL A  27;ALA A  40;MET A  96;LEU A 144;ASP A 155","ADP A 500 (-4.3A);ADP A 500 (-4.3A);ADP A 500 ( 3.7A);None;ADP A 500 (-4.3A);ADP A 500 ( 2.9A)","0.72A","4ansA-2f9gA:22.2","4ansA-2f9gA:23.10"],["4ANS_A_VGHA9000_1","2h8h","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",8,"LEU A 273;VAL A 281;ALA A 293;MET A 341;GLY A 344;LEU A 393;ALA A 403;ASP A 404","H8H A 534 (-3.8A);H8H A 534 (-4.4A);H8H A 534 (-3.2A);None;H8H A 534 (-3.3A);H8H A 534 (-4.5A);H8H A 534 ( 4.0A);H8H A 534 (-4.2A)","0.77A","4ansA-2h8hA:29.9","4ansA-2h8hA:24.20"],["4ANS_A_VGHA9000_1","2hck","Homo sapiens","HEMATOPOETIC CELL KINASE HCK","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",7,"LEU A 273;VAL A 281;ALA A 293;MET A 341;GLY A 344;LEU A 393;ALA A 403","QUE A   1 (-3.9A);QUE A   1 ( 4.8A);QUE A   1 (-3.5A);None;QUE A   1 (-3.0A);QUE A   1 (-4.4A);QUE A   1 ( 4.5A)","0.79A","4ansA-2hckA:28.9","4ansA-2hckA:27.35"],["4ANS_A_VGHA9000_1","2hk5","Homo sapiens","TYROSINE-PROTEIN KINASE HCK","PF07714(Pkinase_Tyr)",8,"LEU A 251;VAL A 259;ALA A 271;MET A 319;GLY A 322;LEU A 371;ALA A 381;ASP A 382","1BM A 499 ( 3.7A);1BM A 499 ( 4.8A);1BM A 499 (-3.6A);None;1BM A 499 (-3.5A);1BM A 499 (-4.4A);1BM A 499 ( 3.7A);1BM A 499 (-4.4A)","0.56A","4ansA-2hk5A:24.9","4ansA-2hk5A:37.30"],["4ANS_A_VGHA9000_1","2hz0","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","PF07714(Pkinase_Tyr)",8,"LEU A 248;VAL A 256;ALA A 269;MET A 318;GLY A 321;LEU A 370;ALA A 380;ASP A 381","GIN A 600 ( 4.6A);GIN A 600 ( 4.7A);GIN A 600 (-3.1A);None;None;GIN A 600 (-4.7A);GIN A 600 (-3.1A);GIN A 600 (-4.9A)","0.96A","4ansA-2hz0A:30.7","4ansA-2hz0A:35.96"],["4ANS_A_VGHA9000_1","2og8","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE LCK","PF07714(Pkinase_Tyr)",7,"LEU A 251;VAL A 259;ALA A 271;MET A 319;GLY A 322;LEU A 371;ALA A 381","None;None;1N8 A 501 ( 3.4A);1N8 A 501 ( 4.4A);1N8 A 501 ( 3.5A);1N8 A 501 ( 4.3A);1N8 A 501 ( 3.3A)","0.88A","4ansA-2og8A:30.1","4ansA-2og8A:40.48"],["4ANS_A_VGHA9000_1","2ozo","Homo sapiens","TYROSINE-PROTEIN KINASE ZAP-70","PF00017(SH2);PF07714(Pkinase_Tyr)",6,"LEU A 344;VAL A 352;ALA A 367;MET A 414;GLY A 420;LEU A 468","ANP A 615 (-4.4A);ANP A 615 (-4.5A);ANP A 615 (-3.3A);ANP A 615 ( 3.9A);ANP A 615 ( 3.9A);ANP A 615 (-4.7A)","0.63A","4ansA-2ozoA:24.6","4ansA-2ozoA:21.94"],["4ANS_A_VGHA9000_1","2phk","Oryctolagus cuniculus","PHOSPHORYLASE KINASE","PF00069(Pkinase)",7,"LEU A  25;VAL A  33;ALA A  46;MET A 106;GLY A 109;LEU A 156;ASP A 167","ATP A 381 ( 4.3A);ATP A 381 (-4.1A);ATP A 381 (-3.5A);None;None;ATP A 381 ( 4.8A); MN A 382 (-2.0A)","0.72A","4ansA-2phkA:22.6","4ansA-2phkA:23.40"],["4ANS_A_VGHA9000_1","2psq","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",6,"LEU A 487;VAL A 495;ALA A 515;GLY A 570;LEU A 633;ALA A 643","None","0.55A","4ansA-2psqA:31.6","4ansA-2psqA:36.15"],["4ANS_A_VGHA9000_1","2qkw","Solanum pimpinellifolium","PROTEIN KINASE","PF07714(Pkinase_Tyr)",6,"VAL B  55;ALA B  67;MET B 117;GLY B 120;LEU B 171;ASP B 182","None","0.61A","4ansA-2qkwB:24.1","4ansA-2qkwB:27.20"],["4ANS_A_VGHA9000_1","2qob","Homo sapiens","EPHRIN RECEPTOR","PF07714(Pkinase_Tyr)",6,"VAL A 635;ALA A 651;MET A 702;GLY A 705;LEU A 753;ASP A 764","BME A   1 (-4.9A);PTR A 701 ( 4.7A);PTR A 701 ( 3.5A);None;None;None","0.41A","4ansA-2qobA:34.0","4ansA-2qobA:32.56"],["4ANS_A_VGHA9000_1","2r2p","Homo sapiens","EPHRIN TYPE-A RECEPTOR 5","PF07714(Pkinase_Tyr);PF14575(EphA2_TM)",6,"VAL A 689;ALA A 705;MET A 756;GLY A 759;LEU A 807;ASP A 818","None","0.32A","4ansA-2r2pA:34.1","4ansA-2r2pA:32.86"],["4ANS_A_VGHA9000_1","2r4b","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-4","PF07714(Pkinase_Tyr)",6,"LEU A 724;VAL A 732;ALA A 749;MET A 799;GLY A 802;LEU A 850","GW7 A   1 ( 4.2A);GW7 A   1 ( 4.8A);GW7 A   1 (-3.3A);None;GW7 A   1 (-3.6A);GW7 A   1 (-4.2A)","0.57A","4ansA-2r4bA:30.0","4ansA-2r4bA:33.53"],["4ANS_A_VGHA9000_1","2v55","Homo sapiens","RHO-ASSOCIATED PROTEIN KINASE 1","PF00069(Pkinase)",7,"VAL A  90;ALA A 103;MET A 153;MET A 156;GLY A 159;ALA A 215;ASP A 216","None;ANP A1480 ( 3.9A);ANP A1480 (-4.1A);None;None;ANP A1480 ( 4.1A);ANP A1480 (-3.5A)","0.88A","4ansA-2v55A:19.5","4ansA-2v55A:23.96"],["4ANS_A_VGHA9000_1","2v55","Homo sapiens","RHO-ASSOCIATED PROTEIN KINASE 1","PF00069(Pkinase)",7,"VAL A  90;ALA A 103;MET A 156;GLY A 159;LEU A 205;ALA A 215;ASP A 216","None;ANP A1480 ( 3.9A);None;None;ANP A1480 ( 4.7A);ANP A1480 ( 4.1A);ANP A1480 (-3.5A)","0.99A","4ansA-2v55A:19.5","4ansA-2v55A:23.96"],["4ANS_A_VGHA9000_1","2xk9","Homo sapiens","CHECKPOINT KINASE 2","PF00069(Pkinase)",7,"LEU A 226;VAL A 234;ALA A 247;MET A 304;GLY A 307;LEU A 354;ASP A 368","XK9 A1511 (-3.8A);XK9 A1511 (-4.8A);XK9 A1511 ( 4.1A);None;XK9 A1511 ( 3.7A);XK9 A1511 (-4.6A);XK9 A1511 (-3.6A)","0.76A","4ansA-2xk9A:21.3","4ansA-2xk9A:24.80"],["4ANS_A_VGHA9000_1","2xyu","Mus musculus","EPHRIN TYPE-A RECEPTOR 4,","PF07714(Pkinase_Tyr)",6,"VAL A 635;ALA A 651;MET A 702;GLY A 705;LEU A 753;ASP A 764","Q9G A1898 ( 4.7A);Q9G A1898 (-3.2A);None;Q9G A1898 ( 3.8A);Q9G A1898 (-4.3A);None","0.58A","4ansA-2xyuA:27.2","4ansA-2xyuA:34.80"],["4ANS_A_VGHA9000_1","2z8c","Homo sapiens","INSULIN RECEPTOR","PF07714(Pkinase_Tyr)",7,"LEU A1002;VAL A1010;ALA A1028;MET A1076;MET A1079;GLY A1082;ASP A1150","S91 A   1 ( 4.1A);S91 A   1 ( 4.9A);S91 A   1 (-3.2A);S91 A   1 ( 4.9A);None;S91 A   1 (-3.3A);None","0.67A","4ansA-2z8cA:30.1","4ansA-2z8cA:44.41"],["4ANS_A_VGHA9000_1","2zv7","Mus musculus","TYROSINE-PROTEIN KINASE LYN","PF07714(Pkinase_Tyr)",8,"LEU A 253;VAL A 261;ALA A 273;MET A 322;GLY A 325;LEU A 374;ALA A 384;ASP A 385","None","0.47A","4ansA-2zv7A:32.4","4ansA-2zv7A:34.49"],["4ANS_A_VGHA9000_1","3b2t","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 2","PF07714(Pkinase_Tyr)",6,"LEU A 487;VAL A 495;ALA A 515;GLY A 570;LEU A 633;ALA A 643","M33 A1996 (-4.0A);M33 A1996 ( 4.7A);M33 A1996 (-3.3A);M33 A1996 ( 4.8A);M33 A1996 (-4.5A);None","0.54A","4ansA-3b2tA:24.5","4ansA-3b2tA:35.21"],["4ANS_A_VGHA9000_1","3d7u","Homo sapiens","TYROSINE-PROTEIN KINASE CSK","PF07714(Pkinase_Tyr)",6,"VAL A 209;ALA A 220;MET A 269;GLY A 272;LEU A 321;ASP A 332","None","0.71A","4ansA-3d7uA:27.3","4ansA-3d7uA:32.94"],["4ANS_A_VGHA9000_1","3fme","Homo sapiens","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6","PF00069(Pkinase)",6,"LEU A  59;VAL A  67;ALA A  80;MET A 129;MET A 132;LEU A 186","STU A   1 (-3.8A);None;STU A   1 (-3.4A);STU A   1 ( 3.8A);None;STU A   1 (-4.4A)","0.57A","4ansA-3fmeA:21.1","4ansA-3fmeA:27.06"],["4ANS_A_VGHA9000_1","3g2f","Homo sapiens","BONE MORPHOGENETIC PROTEIN RECEPTOR TYPE-2","PF00069(Pkinase)",6,"VAL A 217;ALA A 228;MET A 279;GLY A 285;LEU A 340;ASP A 351","ADP A 900 (-4.3A);ADP A 900 (-3.4A);ADP A 900 (-3.6A);ADP A 900 ( 4.2A);ADP A 900 (-4.6A);ADP A 900 ( 2.7A)","0.64A","4ansA-3g2fA:18.4","4ansA-3g2fA:26.86"],["4ANS_A_VGHA9000_1","3lw0","Homo sapiens","INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR","PF07714(Pkinase_Tyr)",6,"LEU A1005;VAL A1013;ALA A1031;MET A1079;MET A1082;GLY A1085","None;None;None;CCX A   1 ( 3.9A);None;None","0.45A","4ansA-3lw0A:29.9","4ansA-3lw0A:39.89"],["4ANS_A_VGHA9000_1","3niz","Cryptosporidium parvum","RHODANESE FAMILY PROTEIN","PF00069(Pkinase)",6,"VAL A  37;ALA A  49;MET A 101;LEU A 151;ALA A 161;ASP A 162","ADP A 314 (-4.0A);ADP A 314 (-3.5A);None;ADP A 314 (-4.6A);None; MG A 312 ( 3.3A)","0.52A","4ansA-3nizA:24.3","4ansA-3nizA:29.30"],["4ANS_A_VGHA9000_1","3nyo","Homo sapiens","G PROTEIN-COUPLED RECEPTOR KINASE 6","PF00069(Pkinase);PF00615(RGS)",7,"LEU A 192;VAL A 200;ALA A 213;MET A 266;GLY A 269;LEU A 318;ASP A 329","AMP A 577 ( 4.3A);AMP A 577 (-4.3A);AMP A 577 (-3.4A);None;None;AMP A 577 (-4.8A);AMP A 577 (-4.0A)","0.75A","4ansA-3nyoA:22.6","4ansA-3nyoA:21.18"],["4ANS_A_VGHA9000_1","3pp0","Homo sapiens","RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2","PF07714(Pkinase_Tyr)",6,"LEU A 726;VAL A 734;ALA A 751;MET A 801;GLY A 804;LEU A 852","03Q A   1 (-3.8A);03Q A   1 (-4.5A);03Q A   1 (-3.1A);None;03Q A   1 ( 3.9A);03Q A   1 (-4.4A)","0.52A","4ansA-3pp0A:31.1","4ansA-3pp0A:33.24"],["4ANS_A_VGHA9000_1","3she","Homo sapiens","MAP KINASE-ACTIVATED PROTEIN KINASE 3","PF00069(Pkinase)",7,"LEU A  50;VAL A  58;ALA A  71;MET A 118;MET A 121;GLY A 124;LEU A 173","I85 A 350 (-3.7A);I85 A 350 (-4.9A);I85 A 350 (-3.3A);I85 A 350 ( 3.9A);None;I85 A 350 (-3.0A);None","1.01A","4ansA-3sheA:19.6","4ansA-3sheA:23.77"],["4ANS_A_VGHA9000_1","3ulz","Arabidopsis thaliana","BRASSINOSTEROID INSENSITIVE 1-ASSOCIATED RECEPTOR KINASE 1","PF00069(Pkinase)",6,"LEU A 295;VAL A 303;ALA A 315;MET A 366;GLY A 369;LEU A 423","None","0.53A","4ansA-3ulzA:22.1","4ansA-3ulzA:27.69"],["4ANS_A_VGHA9000_1","3v5q","Homo sapiens","NT-3 GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",6,"LEU A 544;VAL A 552;ALA A 570;MET A 620;GLY A 623;LEU A 686","0F4 A 902 ( 4.2A);None;0F4 A 902 (-3.2A);None;0F4 A 902 (-3.4A);0F4 A 902 (-4.5A)","0.31A","4ansA-3v5qA:14.8","4ansA-3v5qA:37.32"],["4ANS_A_VGHA9000_1","3vn9","Homo sapiens","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6","PF00069(Pkinase)",6,"LEU A  59;VAL A  67;ALA A  80;MET A 129;MET A 132;LEU A 186","None;ANK A 401 (-4.3A);ANK A 401 (-3.0A);ANK A 401 (-3.7A);None;ANK A 401 ( 4.9A)","0.69A","4ansA-3vn9A:21.6","4ansA-3vn9A:26.80"],["4ANS_A_VGHA9000_1","3wig","Homo sapiens","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","PF00069(Pkinase)",7,"LEU A  75;VAL A  83;ALA A  96;MET A 144;MET A 147;GLY A 150;LEU A 198","ANP A 401 (-3.8A);ANP A 401 ( 4.3A);ANP A 401 (-3.2A);CHU A 403 (-3.8A);None;ANP A 401 ( 4.3A);ANP A 401 (-4.8A)","0.44A","4ansA-3wigA:22.9","4ansA-3wigA:24.27"],["4ANS_A_VGHA9000_1","3zbf","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS","PF07714(Pkinase_Tyr)",7,"LEU A1951;VAL A1959;ALA A1978;MET A2029;GLY A2032;LEU A2086;ASP A2102","VGH A3000 ( 4.4A);None;VGH A3000 (-3.4A);None;VGH A3000 (-3.5A);VGH A3000 (-4.3A);None","0.33A","4ansA-3zbfA:34.4","4ansA-3zbfA:49.27"],["4ANS_A_VGHA9000_1","3zfx","Homo sapiens","EPHRIN TYPE-B RECEPTOR 1","PF07714(Pkinase_Tyr)",6,"VAL A 633;ALA A 649;MET A 700;GLY A 703;LEU A 751;ASP A 762","None","0.44A","4ansA-3zfxA:34.3","4ansA-3zfxA:35.10"],["4ANS_A_VGHA9000_1","4af3","Homo sapiens","AURORA KINASE B","PF00069(Pkinase)",6,"LEU A  83;VAL A  91;ALA A 104;GLY A 160;LEU A 207;ALA A 217","VX6 A 500 (-3.8A);VX6 A 500 ( 4.8A);VX6 A 500 (-3.4A);VX6 A 500 (-3.3A);VX6 A 500 (-4.6A);VX6 A 500 ( 4.2A)","0.60A","4ansA-4af3A:19.7","4ansA-4af3A:24.42"],["4ANS_A_VGHA9000_1","4at3","Homo sapiens","BDNF\/NT-3 GROWTH FACTORS RECEPTOR","PF07714(Pkinase_Tyr)",7,"LEU A 560;VAL A 568;ALA A 586;MET A 636;GLY A 639;LEU A 699;ASP A 710","LTI A1839 ( 4.2A);None;LTI A1839 (-3.3A);None;LTI A1839 (-3.4A);LTI A1839 (-4.2A);None","0.47A","4ansA-4at3A:31.0","4ansA-4at3A:36.78"],["4ANS_A_VGHA9000_1","4aw5","Homo sapiens","EPHRIN TYPE-B RECEPTOR 4","PF07714(Pkinase_Tyr)",6,"VAL A 105;ALA A 121;MET A 172;GLY A 175;LEU A 223;ASP A 234","30K A1365 ( 4.6A);30K A1365 (-3.2A);None;30K A1365 (-3.5A);30K A1365 (-4.5A);30K A1365 (-3.3A)","0.35A","4ansA-4aw5A:33.8","4ansA-4aw5A:34.53"],["4ANS_A_VGHA9000_1","4bc6","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 10","PF00069(Pkinase)",6,"LEU A  42;VAL A  50;ALA A  63;GLY A 116;LEU A 164;ALA A 174","XZN A1317 (-3.6A);XZN A1317 ( 4.7A);XZN A1317 (-3.5A);XZN A1317 ( 3.7A);XZN A1317 (-4.7A);XZN A1317 ( 4.3A)","0.53A","4ansA-4bc6A:23.5","4ansA-4bc6A:27.52"],["4ANS_A_VGHA9000_1","4crs","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE N2","PF00069(Pkinase);PF00433(Pkinase_C)",8,"LEU A 663;VAL A 671;ALA A 684;MET A 737;GLY A 743;LEU A 789;ALA A 799;ASP A 800","AGS A1985 (-4.2A);AGS A1985 (-4.6A);AGS A1985 (-3.5A);AGS A1985 (-4.2A);None;AGS A1985 (-4.8A);AGS A1985 ( 4.5A);AGS A1985 ( 3.3A)","0.78A","4ansA-4crsA:21.6","4ansA-4crsA:27.18"],["4ANS_A_VGHA9000_1","4f0i","Homo sapiens","HIGH AFFINITY NERVE GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",7,"LEU A 515;VAL A 523;ALA A 541;MET A 591;GLY A 594;LEU A 656;ASP A 667","None","0.59A","4ansA-4f0iA:30.8","4ansA-4f0iA:37.24"],["4ANS_A_VGHA9000_1","4f4p","Homo sapiens","TYROSINE-PROTEIN KINASE SYK","PF07714(Pkinase_Tyr)",7,"LEU A 377;VAL A 385;ALA A 400;MET A 448;GLY A 454;LEU A 501;ASP A 512","0SB A 701 ( 3.9A);0SB A 701 (-4.0A);0SB A 701 (-3.3A);0SB A 701 (-3.6A);0SB A 701 (-3.5A);0SB A 701 (-4.4A);0SB A 701 (-3.9A)","0.65A","4ansA-4f4pA:31.4","4ansA-4f4pA:31.69"],["4ANS_A_VGHA9000_1","4feq","Mus musculus","TYROSINE-PROTEIN KINASE RECEPTOR TYRO3","PF07714(Pkinase_Tyr)",7,"LEU A 514;VAL A 522;ALA A 538;MET A 596;GLY A 599;ALA A 662;ASP A 663","0T8 A 901 (-3.6A);0T8 A 901 ( 4.4A);0T8 A 901 (-3.2A);None;0T8 A 901 ( 3.8A);0T8 A 901 ( 4.5A);0T8 A 901 (-4.5A)","0.86A","4ansA-4feqA:22.2","4ansA-4feqA:35.81"],["4ANS_A_VGHA9000_1","4fl3","Homo sapiens","TYROSINE-PROTEIN KINASE SYK","PF00017(SH2);PF07714(Pkinase_Tyr)",6,"LEU A 377;VAL A 385;ALA A 400;MET A 448;GLY A 454;LEU A 501","ANP A 701 ( 4.6A);ANP A 701 (-4.1A);ANP A 701 (-3.3A);ANP A 701 ( 3.7A);ANP A 701 ( 4.2A);ANP A 701 (-4.5A)","0.42A","4ansA-4fl3A:29.4","4ansA-4fl3A:20.66"],["4ANS_A_VGHA9000_1","4fod","Homo sapiens","ALK TYROSINE KINASE RECEPTOR","PF07714(Pkinase_Tyr)",7,"LEU A1122;VAL A1130;ALA A1148;MET A1199;GLY A1202;LEU A1256;ASP A1270","0UV A1501 (-3.8A);0UV A1501 (-4.5A);0UV A1501 (-3.4A);None;0UV A1501 (-3.6A);0UV A1501 (-4.6A);0UV A1501 ( 4.2A)","0.34A","4ansA-4fodA:46.3","4ansA-4fodA:93.26"],["4ANS_A_VGHA9000_1","4gl9","Mus musculus","TYROSINE-PROTEIN KINASE","PF07714(Pkinase_Tyr)",6,"LEU A 855;VAL A 863;ALA A 880;MET A 929;GLY A 935;LEU A 983","IZA A2001 (-3.7A);None;IZA A2001 (-3.4A);IZA A2001 (-4.4A);IZA A2001 (-3.3A);IZA A2001 ( 4.7A)","0.61A","4ansA-4gl9A:28.8","4ansA-4gl9A:29.91"],["4ANS_A_VGHA9000_1","4hvi","Homo sapiens","TYROSINE-PROTEIN KINASE JAK3","PF07714(Pkinase_Tyr)",6,"ALA A 853;MET A 902;GLY A 908;LEU A 956;ALA A 966;ASP A 967","19S A1201 (-3.3A);19S A1201 (-3.6A);19S A1201 ( 3.8A);19S A1201 (-4.5A);19S A1201 ( 4.1A);19S A1201 ( 4.1A)","0.54A","4ansA-4hviA:29.7","4ansA-4hviA:28.73"],["4ANS_A_VGHA9000_1","4hvi","Homo sapiens","TYROSINE-PROTEIN KINASE JAK3","PF07714(Pkinase_Tyr)",7,"LEU A 828;VAL A 836;ALA A 853;MET A 902;GLY A 908;LEU A 956;ALA A 966","19S A1201 (-3.9A);19S A1201 (-4.4A);19S A1201 (-3.3A);19S A1201 (-3.6A);19S A1201 ( 3.8A);19S A1201 (-4.5A);19S A1201 ( 4.1A)","0.80A","4ansA-4hviA:29.7","4ansA-4hviA:28.73"],["4ANS_A_VGHA9000_1","4id7","Homo sapiens","ACTIVATED CDC42 KINASE 1","PF07714(Pkinase_Tyr)",6,"LEU A 132;VAL A 140;ALA A 156;GLY A 211;LEU A 259;ASP A 270","1G0 A 401 ( 4.5A);1G0 A 401 (-4.4A);1G0 A 401 (-3.6A);1G0 A 401 ( 4.5A);1G0 A 401 (-4.6A);None","0.64A","4ansA-4id7A:30.9","4ansA-4id7A:33.63"],["4ANS_A_VGHA9000_1","4jrn","Toxoplasma gondii","RHOPTRY KINASE FAMILY PROTEIN","PF14531(Kinase-like)",6,"LEU A 258;VAL A 266;ALA A 279;MET A 356;LEU A 416;ASP A 427","ANP A 601 ( 4.6A);ANP A 601 (-4.1A);ANP A 601 ( 3.9A);ANP A 601 (-3.3A);ANP A 601 ( 4.9A); MG A 603 ( 2.0A)","0.53A","4ansA-4jrnA:19.8","4ansA-4jrnA:24.23"],["4ANS_A_VGHA9000_1","4jxf","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE PLK4","PF00069(Pkinase)",7,"LEU A  18;VAL A  26;ALA A  39;GLY A  95;LEU A 143;ALA A 153;ASP A 154","631 A 301 (-3.4A);631 A 301 (-4.6A);631 A 301 (-3.3A);631 A 301 ( 3.7A);631 A 301 (-4.0A);631 A 301 (-3.4A);EDO A 302 (-3.7A)","0.67A","4ansA-4jxfA:18.8","4ansA-4jxfA:23.89"],["4ANS_A_VGHA9000_1","4k11","Homo sapiens","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",7,"LEU A 273;VAL A 281;ALA A 293;MET A 341;GLY A 344;LEU A 393;ALA A 403","0J9 A 601 (-4.0A);0J9 A 601 (-4.4A);0J9 A 601 (-3.3A);None;0J9 A 601 ( 4.1A);0J9 A 601 (-4.5A);0J9 A 601 (-3.5A)","0.56A","4ansA-4k11A:29.8","4ansA-4k11A:27.73"],["4ANS_A_VGHA9000_1","4k33","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 3","PF07714(Pkinase_Tyr)",7,"LEU A 478;VAL A 486;ALA A 506;GLY A 561;LEU A 624;ALA A 634;ASP A 635","ACP A 801 (-3.8A);ACP A 801 (-4.2A);ACP A 801 (-3.3A);ACP A 801 ( 4.6A);ACP A 801 (-4.4A);None; MG A 802 ( 3.0A)","0.66A","4ansA-4k33A:32.2","4ansA-4k33A:37.96"],["4ANS_A_VGHA9000_1","4lg4","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 3","PF00069(Pkinase)",7,"LEU A  33;VAL A  41;ALA A  54;MET A  99;GLY A 105;LEU A 153;ALA A 163","GOL A 404 ( 3.6A);GOL A 404 (-4.5A);GOL A 404 ( 3.1A);GOL A 403 (-2.7A);GOL A 404 (-3.6A);GOL A 403 ( 4.4A);GOL A 403 ( 3.0A)","0.63A","4ansA-4lg4A:18.2","4ansA-4lg4A:26.63"],["4ANS_A_VGHA9000_1","4lgg","Gallus gallus","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC","PF07714(Pkinase_Tyr)",7,"LEU A 273;VAL A 281;ALA A 293;MET A 341;GLY A 344;LEU A 393;ALA A 403","VGG A 601 (-3.2A);VGG A 601 ( 3.5A);VGG A 601 (-3.5A);None;VGG A 601 ( 3.2A);VGG A 601 (-4.5A);VGG A 601 ( 4.2A)","0.44A","4ansA-4lggA:29.8","4ansA-4lggA:33.24"],["4ANS_A_VGHA9000_1","4o27","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 24","PF00069(Pkinase)",6,"VAL B  38;ALA B  51;MET B  99;LEU B 151;ALA B 161;ASP B 162","ADP B 500 (-4.5A);ADP B 500 (-3.3A);ADP B 500 ( 4.1A);ADP B 500 (-4.7A);None;ADP B 500 ( 3.4A)","0.59A","4ansA-4o27B:18.2","4ansA-4o27B:26.01"],["4ANS_A_VGHA9000_1","4oli","Homo sapiens","NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2","PF07714(Pkinase_Tyr)",6,"LEU A 903;VAL A 911;ALA A 928;MET A 978;GLY A 984;LEU A1030","2TT A1202 (-3.5A);2TT A1202 (-4.5A);2TT A1202 ( 3.9A);2TT A1202 ( 4.4A);2TT A1202 (-3.4A);2TT A1202 (-4.4A)","0.71A","4ansA-4oliA:27.1","4ansA-4oliA:23.40"],["4ANS_A_VGHA9000_1","4otd","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE N1","PF00069(Pkinase);PF00433(Pkinase_C)",7,"LEU A 627;VAL A 635;ALA A 648;GLY A 707;LEU A 753;ALA A 763;ASP A 764","None","1.13A","4ansA-4otdA:21.9","4ansA-4otdA:27.30"],["4ANS_A_VGHA9000_1","4p2k","Homo sapiens","EPHRIN TYPE-A RECEPTOR 2","PF07714(Pkinase_Tyr);PF14575(EphA2_TM)",6,"VAL A 627;ALA A 644;MET A 695;GLY A 698;LEU A 746;ASP A 757","None","0.50A","4ansA-4p2kA:34.5","4ansA-4p2kA:36.58"],["4ANS_A_VGHA9000_1","4qny","Leishmania donovani","MITOGEN ACTIVATED PROTEIN KINASE, PUTATIVE","PF00069(Pkinase)",6,"VAL A  35;ALA A  49;MET A 104;MET A 107;LEU A 156;ASP A 167","ANP A 402 (-4.3A);ANP A 402 (-3.3A);ANP A 402 (-4.4A);None;ANP A 402 (-4.6A);ANP A 402 ( 2.6A)","0.60A","4ansA-4qnyA:22.4","4ansA-4qnyA:25.06"],["4ANS_A_VGHA9000_1","4ueu","synthetic construct","TYROSINE KINASE AS - A COMMON ANCESTOR OF SRC AND ABL","PF07714(Pkinase_Tyr)",8,"LEU A  14;VAL A  22;ALA A  35;MET A  84;GLY A  87;LEU A 136;ALA A 146;ASP A 147","ACP A1264 ( 4.5A);ACP A1264 (-4.7A);ACP A1264 (-2.9A);None;ACP A1264 (-3.5A);ACP A1264 ( 4.8A);None;None","0.48A","4ansA-4ueuA:32.2","4ansA-4ueuA:39.47"],["4ANS_A_VGHA9000_1","4usf","Homo sapiens","STE20-LIKE SERINE\/THREONINE-PROTEIN KINASE","PF00069(Pkinase)",6,"LEU A  40;VAL A  48;ALA A  61;GLY A 114;LEU A 162;ALA A 172","6UI A 700 ( 4.9A);None;6UI A 700 (-3.3A);6UI A 700 ( 4.2A);6UI A 700 (-4.2A);6UI A 700 ( 4.1A)","0.56A","4ansA-4usfA:23.5","4ansA-4usfA:28.57"],["4ANS_A_VGHA9000_1","4wbo","Bos taurus","RHODOPSIN KINASE","PF00069(Pkinase);PF00615(RGS)",8,"LEU A 193;VAL A 201;ALA A 214;MET A 264;MET A 267;GLY A 270;LEU A 321;ASP A 332","ANW A 601 ( 4.0A);None;ANW A 601 (-3.4A);ANW A 601 (-3.2A);None;ANW A 601 ( 4.5A);ANW A 601 (-4.9A);None","0.65A","4ansA-4wboA:23.3","4ansA-4wboA:22.39"],["4ANS_A_VGHA9000_1","4wsq","Homo sapiens","AP2-ASSOCIATED PROTEIN KINASE 1","PF00069(Pkinase)",7,"LEU A  52;VAL A  60;ALA A  72;MET A 126;GLY A 132;LEU A 183;ASP A 194","KSA A 405 ( 4.0A);KSA A 405 ( 4.9A);KSA A 405 (-3.2A);KSA A 405 ( 3.7A);KSA A 405 (-3.5A);KSA A 405 (-4.6A); ZN A 403 ( 2.6A)","0.87A","4ansA-4wsqA:23.4","4ansA-4wsqA:24.52"],["4ANS_A_VGHA9000_1","4xey","Homo sapiens","TYROSINE-PROTEIN KINASE ABL1","no annotation",6,"LEU B 267;VAL B 275;ALA B 288;GLY B 340;LEU B 389;ALA B 399","1N1 B 601 (-3.7A);1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);1N1 B 601 (-3.5A);1N1 B 601 (-4.3A);1N1 B 601 (-3.5A)","0.65A","4ansA-4xeyB:25.5","4ansA-4xeyB:32.86"],["4ANS_A_VGHA9000_1","4xey","Homo sapiens","TYROSINE-PROTEIN KINASE ABL1","no annotation",6,"LEU B 267;VAL B 275;ALA B 288;MET B 337;GLY B 340;LEU B 389","1N1 B 601 (-3.7A);1N1 B 601 ( 4.9A);1N1 B 601 (-3.5A);None;1N1 B 601 (-3.5A);1N1 B 601 (-4.3A)","0.34A","4ansA-4xeyB:25.5","4ansA-4xeyB:32.86"],["4ANS_A_VGHA9000_1","4xi2","Mus musculus","TYROSINE-PROTEIN KINASE BTK","PF00017(SH2);PF00018(SH3_1);PF07714(Pkinase_Tyr)",6,"LEU A 408;VAL A 416;ALA A 428;MET A 477;GLY A 480;LEU A 528","None","0.66A","4ansA-4xi2A:31.2","4ansA-4xi2A:27.52"],["4ANS_A_VGHA9000_1","4y93","Bos taurus","NON-SPECIFIC PROTEIN-TYROSINE KINASE,NON-SPECIFIC PROTEIN-TYROSINE KINASE","PF00169(PH);PF00779(BTK);PF07714(Pkinase_Tyr)",6,"LEU A 408;VAL A 416;ALA A 428;MET A 477;GLY A 480;LEU A 528","746 A 702 (-3.8A);746 A 702 ( 4.3A);746 A 702 (-2.4A);None;746 A 702 (-3.6A);746 A 702 (-4.4A)","0.31A","4ansA-4y93A:31.4","4ansA-4y93A:27.78"],["4ANS_A_VGHA9000_1","4yhj","Homo sapiens","G PROTEIN-COUPLED RECEPTOR KINASE 4","PF00069(Pkinase);PF00615(RGS)",6,"LEU A 193;VAL A 201;ALA A 214;MET A 267;LEU A 319;ASP A 330","AN2 A 601 ( 4.2A);AN2 A 601 (-4.0A);AN2 A 601 (-3.6A);None;None;AN2 A 601 (-3.0A)","0.52A","4ansA-4yhjA:21.3","4ansA-4yhjA:21.36"],["4ANS_A_VGHA9000_1","5a46","Homo sapiens","FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B","PF07714(Pkinase_Tyr)",6,"LEU A 484;VAL A 492;ALA A 512;GLY A 567;LEU A 630;ALA A 640","38O A1769 (-3.2A);38O A1769 (-4.5A);38O A1769 (-3.6A);38O A1769 (-3.4A);38O A1769 (-4.6A);EDO A1766 ( 4.4A)","0.63A","4ansA-5a46A:31.3","4ansA-5a46A:35.24"],["4ANS_A_VGHA9000_1","5eyk","Xenopus laevis","AURORA KINASE B-A","PF00069(Pkinase)",7,"LEU A  99;VAL A 107;ALA A 120;GLY A 176;LEU A 223;ALA A 233;ASP A 234","5U5 A 401 (-3.8A);5U5 A 401 ( 4.3A);5U5 A 401 (-3.5A);5U5 A 401 (-3.4A);5U5 A 401 (-4.7A);None;None","0.70A","4ansA-5eykA:24.5","4ansA-5eykA:27.27"],["4ANS_A_VGHA9000_1","5f1z","Homo sapiens","NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2","PF07714(Pkinase_Tyr)",6,"LEU A 903;VAL A 911;ALA A 928;MET A 978;GLY A 984;LEU A1030","5U3 A1200 (-3.8A);5U3 A1200 ( 4.4A);5U3 A1200 (-3.5A);5U3 A1200 ( 4.0A);5U3 A1200 (-3.2A);5U3 A1200 (-4.4A)","0.60A","4ansA-5f1zA:27.7","4ansA-5f1zA:31.39"],["4ANS_A_VGHA9000_1","5hor","Homo sapiens","HEPATOCYTE GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",6,"VAL A1092;ALA A1108;MET A1160;GLY A1163;ALA A1221;ASP A1222","63K A1401 (-4.9A);63K A1401 (-3.5A);None;63K A1401 (-3.6A);63K A1401 (-3.3A);None","0.59A","4ansA-5horA:25.7","4ansA-5horA:33.14"],["4ANS_A_VGHA9000_1","5hu3","Drosophila melanogaster","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE TYPE II ALPHA CHAIN","PF00069(Pkinase)",7,"LEU A  20;VAL A  28;ALA A  41;GLY A  96;LEU A 143;ALA A 156;ASP A 157","ADP A 301 ( 4.0A);ADP A 301 (-3.7A);ADP A 301 (-3.5A);None;ADP A 301 (-4.7A);ADP A 301 ( 4.8A); MG A 302 ( 3.3A)","0.86A","4ansA-5hu3A:24.7","4ansA-5hu3A:25.36"],["4ANS_A_VGHA9000_1","5i3o","Homo sapiens","BMP-2-INDUCIBLE PROTEIN KINASE","PF00069(Pkinase)",6,"LEU A  57;VAL A  65;ALA A  77;MET A 130;GLY A 136;LEU A 187","IDV A 401 (-3.8A);IDV A 401 (-4.6A);IDV A 401 (-3.6A);IDV A 401 (-3.4A);IDV A 401 (-3.4A);IDV A 401 (-4.4A)","0.45A","4ansA-5i3oA:23.6","4ansA-5i3oA:21.72"],["4ANS_A_VGHA9000_1","5j5t","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 3","PF00069(Pkinase)",6,"ALA A  43;MET A  90;GLY A  96;LEU A 143;ALA A 153;ASP A 154","6G2 A 901 (-3.2A);6G2 A 901 (-3.5A);6G2 A 901 (-3.6A);6G2 A 901 (-4.7A);6G2 A 901 ( 4.2A);6G2 A 901 (-3.4A)","0.69A","4ansA-5j5tA:23.2","4ansA-5j5tA:25.06"],["4ANS_A_VGHA9000_1","5j9z","Homo sapiens","EPIDERMAL GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",6,"LEU A 718;VAL A 726;ALA A 743;MET A 790;GLY A 796;LEU A 844","6HJ A1101 ( 4.6A);6HJ A1101 ( 4.7A);6HJ A1101 (-3.1A);6HJ A1101 (-3.4A);6HJ A1101 ( 4.5A);6HJ A1101 ( 4.8A)","0.71A","4ansA-5j9zA:32.4","4ansA-5j9zA:33.14"],["4ANS_A_VGHA9000_1","5j9z","Homo sapiens","EPIDERMAL GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",6,"LEU A 718;VAL A 726;ALA A 743;MET A 793;GLY A 796;ASP A 855","6HJ A1101 ( 4.6A);6HJ A1101 ( 4.7A);6HJ A1101 (-3.1A);None;6HJ A1101 ( 4.5A);6HJ A1101 (-4.3A)","0.62A","4ansA-5j9zA:32.4","4ansA-5j9zA:33.14"],["4ANS_A_VGHA9000_1","5j9z","Homo sapiens","EPIDERMAL GROWTH FACTOR RECEPTOR","PF07714(Pkinase_Tyr)",6,"LEU A 718;VAL A 726;ALA A 743;MET A 793;GLY A 796;LEU A 844","6HJ A1101 ( 4.6A);6HJ A1101 ( 4.7A);6HJ A1101 (-3.1A);None;6HJ A1101 ( 4.5A);6HJ A1101 ( 4.8A)","0.29A","4ansA-5j9zA:32.4","4ansA-5j9zA:33.14"],["4ANS_A_VGHA9000_1","5lpy","Arabidopsis thaliana","PROTEIN BRASSINOSTEROID INSENSITIVE 1","PF00069(Pkinase)",6,"VAL A 897;ALA A 909;MET A 959;GLY A 962;LEU A1016;ASP A1027","ATP A1200 ( 4.5A);ATP A1200 (-3.5A);None;ATP A1200 ( 4.0A);ATP A1200 (-4.6A);ATP A1200 (-4.1A)","0.65A","4ansA-5lpyA:23.1","4ansA-5lpyA:25.98"],["4ANS_A_VGHA9000_1","5lpz","Arabidopsis thaliana","PROTEIN BRASSINOSTEROID INSENSITIVE 1","PF00069(Pkinase)",6,"VAL A 897;ALA A 909;MET A 959;GLY A 962;LEU A1016;ASP A1027","ADP A1200 (-4.4A);ADP A1200 (-3.5A);None;ADP A1200 ( 4.0A);ADP A1200 (-4.7A);ADP A1200 (-3.4A)","0.53A","4ansA-5lpzA:23.1","4ansA-5lpzA:25.66"],["4ANS_A_VGHA9000_1","5td2","Homo sapiens","TYROSINE-PROTEIN KINASE MER","PF07714(Pkinase_Tyr)",7,"LEU A 593;VAL A 601;ALA A 617;MET A 674;GLY A 677;ALA A 740;ASP A 741","7AE A1000 ( 3.9A);7AE A1000 ( 4.9A);7AE A1000 (-3.3A);None;7AE A1000 ( 3.7A);7AE A1000 ( 3.7A);7AE A1000 (-4.4A)","0.57A","4ansA-5td2A:28.9","4ansA-5td2A:34.45"],["4ANS_A_VGHA9000_1","5u6b","Homo sapiens","TYROSINE-PROTEIN KINASE RECEPTOR UFO","PF07714(Pkinase_Tyr)",7,"LEU A 542;VAL A 550;ALA A 565;MET A 623;GLY A 626;ALA A 689;ASP A 690","7YS A9001 (-4.1A);7YS A9001 (-4.2A);7YS A9001 (-3.3A);7YS A9001 (-4.7A);7YS A9001 (-3.4A);7YS A9001 (-3.4A);None","0.61A","4ansA-5u6bA:30.2","4ansA-5u6bA:40.48"],["4ANS_A_VGHA9000_1","5u7q","Homo sapiens","RHO-ASSOCIATED PROTEIN KINASE 2","PF00069(Pkinase)",8,"VAL A 106;ALA A 119;MET A 169;MET A 172;GLY A 175;LEU A 221;ALA A 231;ASP A 232","None","0.69A","4ansA-5u7qA:20.5","4ansA-5u7qA:24.47"],["4ANS_A_VGHA9000_1","5vo1","Homo sapiens","MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 12","PF07714(Pkinase_Tyr)",6,"VAL A 139;ALA A 150;MET A 190;GLY A 196;LEU A 243;ASP A 254","9FS A 501 (-4.5A);9FS A 501 (-3.4A);9FS A 501 (-3.6A);9FS A 501 (-3.6A);9FS A 501 (-4.7A);None","0.66A","4ansA-5vo1A:26.1","4ansA-5vo1A:30.79"],["4ANS_A_VGHA9000_1","5w5j","Homo sapiens","RECEPTOR-INTERACTING SERINE\/THREONINE-PROTEIN KINASE 2","no annotation",6,"LEU A  24;VAL A  32;ALA A  45;MET A  98;GLY A 101;LEU A 153","9WS A 401 ( 4.2A);9WS A 401 ( 4.6A);9WS A 401 (-3.3A);None;9WS A 401 ( 4.3A);9WS A 401 (-4.6A)","0.54A","4ansA-5w5jA:22.7","4ansA-5w5jA:27.22"],["4ANS_A_VGHA9000_1","5wnm","Mus musculus","RECEPTOR-INTERACTING SERINE\/THREONINE-PROTEIN KINASE 4","no annotation",7,"VAL A  36;ALA A  49;MET A  96;MET A  99;GLY A 102;LEU A 150;ASP A 161","VX6 A 402 (-4.6A);VX6 A 402 (-3.2A);VX6 A 402 (-3.7A);None;VX6 A 402 (-3.5A);VX6 A 402 (-4.4A);VX6 A 402 (-4.3A)","0.58A","4ansA-5wnmA:28.1","4ansA-5wnmA:16.67"],["4ANS_A_VGHA9000_1","6ao5","Homo sapiens","SERINE\/THREONINE-PROTEIN KINASE 3","no annotation",7,"LEU A  33;VAL A  41;ALA A  54;MET A  99;GLY A 105;LEU A 153;ALA A 163","ANP A 501 ( 3.8A);ANP A 501 (-4.4A);ANP A 501 ( 3.7A);ANP A 501 (-2.5A);ANP A 501 ( 4.0A);ANP A 501 (-4.6A);None","0.62A","4ansA-6ao5A:22.4","4ansA-6ao5A:24.11"],["4ANS_A_VGHA9000_1","6bql","Homo sapiens","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE KINASE 2","no annotation",6,"VAL A 179;ALA A 192;GLY A 273;LEU A 319;ALA A 329;ASP A 330","BI9 A 501 ( 4.8A);BI9 A 501 (-3.3A);BI9 A 501 (-3.3A);BI9 A 501 (-4.7A);NH4 A 506 ( 3.7A);None","0.68A","4ansA-6bqlA:22.7","4ansA-6bqlA:12.61"],["4ANS_A_VGHA9000_1","6c7y","Homo sapiens","TYROSINE-PROTEIN KINASE JAK1","no annotation",7,"LEU A 881;VAL A 889;ALA A 906;MET A 956;GLY A 962;LEU A1010;ASP A1021","ADP A1201 ( 4.5A);ADP A1201 (-4.3A);ADP A1201 (-3.4A);ADP A1201 (-4.2A);ADP A1201 ( 4.1A);ADP A1201 (-4.5A); MG A1203 (-1.8A)","0.69A","4ansA-6c7yA:28.7","4ansA-6c7yA:15.18"],["4ANS_A_VGHA9000_1","6ccf","Homo sapiens","CALCIUM\/CALMODULIN-DEPENDENT PROTEIN KINASE KINASE 1","no annotation",6,"VAL A 142;ALA A 155;GLY A 236;LEU A 282;ALA A 292;ASP A 293","H1N A 501 (-4.4A);H1N A 501 (-3.4A);H1N A 501 (-3.6A);H1N A 501 (-4.8A);H1N A 501 ( 3.9A);H1N A 501 (-3.5A)","0.56A","4ansA-6ccfA:22.3","4ansA-6ccfA:13.16"],["4ANS_A_VGHA9000_1","6cz4","Homo sapiens","PROTEIN-TYROSINE KINASE 6","no annotation",6,"LEU A 197;VAL A 205;ALA A 217;MET A 267;GLY A 270;LEU A 319","FKY A9001 (-4.1A);FKY A9001 ( 4.6A);FKY A9001 (-3.3A);None;FKY A9001 (-3.3A);FKY A9001 ( 4.9A)","0.67A","4ansA-6cz4A:29.6","4ansA-6cz4A:17.71"],["4ANS_A_VGHA9000_1","6f3d","Homo sapiens","INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4","no annotation",6,"VAL A 200;ALA A 211;MET A 265;GLY A 268;LEU A 318;ASP A 329","CJT A 502 ( 4.8A);CJT A 502 (-3.4A);CJT A 502 (-4.9A);CJT A 502 ( 4.3A);CJT A 502 (-4.7A);CJT A 502 ( 4.0A)","0.63A","4ansA-6f3dA:24.0","4ansA-6f3dA:13.36"],["4ANS_A_VGHA9000_1","6fdy","-","-","no annotation",7,"LEU U  20;VAL U  28;ALA U  42;GLY U  97;LEU U 144;ALA U 156;ASP U 157","DB8 U 301 (-3.7A);DB8 U 301 ( 4.8A);DB8 U 301 (-3.6A);DB8 U 301 ( 4.1A);DB8 U 301 (-4.8A);DB8 U 301 ( 4.2A);DB8 U 301 (-3.6A)","0.72A","4ansA-6fdyU:22.3","4ansA-6fdyU:undetectable"]]